Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Devimistat + mFFX in 2nd Line Metastatic Pancreatic Cancer
NCT06518538Phase 2Withdrawn
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of devimistat in pancreatic adenocarcinoma (PDAC), sponsored by Cornerstone Pharmaceuticals. Planned start Aug 2024; status: withdrawn.
02
Drugs
devimistat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06518538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06518538.